Covid Booster: US to Buy $1.7 Billion of Moderna Omicron-Specific Vaccine (MRNA) - Bloomberg
Moderna on X: "We have submitted a request for emergency use authorization (EUA) for our Omicron-targeting bivalent #COVID19 #vaccine, mRNA-1273.222, in children and adolescents 12 to 17 years of age to the
EMA accepts Moderna's CMA submission for Covid-19 vaccine
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results | Nature Medicine
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results | Nature Medicine
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice | Nature Medicine
dinero.com.sv - Moderna receives FDA clearance for emergency use of Covid-19 booster vaccine
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice | Nature Medicine
Moderna: New booster protects better against variants - The Jerusalem Post
Moderna completes FDA filing for bivalent COVID-19 booster vaccine, MR
Moderna on X: "ANNOUNCEMENT: The U.S. government has secured 66 million doses of our #COVID19 #vaccine booster candidate, mRNA-1273.222, a bivalent booster candidate containing Spikevax™ plus the Omicron BA.4/5 strain mRNA. Read
Moderna on X: "ANNOUNCEMENT 📢: The first participant has been dosed in a Phase 2/3 trial of mRNA-1273.222, a bivalent #COVID19 #booster vaccine candidate targeting the original and #Omicron BA.4/5 strains of
Moderna bivalent COVID-19 booster outperforms original against variants, company says
Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial
Trial Details
Moderna to advance two Omicron vaccine candidates against newer variants | Reuters
Moderna says new booster effective against BA.4/BA.5 subvariants | CTV News
Moderna COVID19 Bivalent vaccine (Original and Omicron BA.4/BA.5)
Moderna to advance two Omicron vaccine candidates against newer variants
Moderna on X: "A Phase 2/3 trial for mRNA-1273.222 is currently underway. We have rapidly scaled manufacturing of mRNA-1273.222 to be ready, if authorized, to deliver doses in September. https://t.co/AQG4hfwNe6" / X
Omicron-tailored shots show better response than original COVID vaccine: Moderna | Mint
CDC Recommends Bivalent COVID 19 Boosters
Moderna Says Omicron Tailored COVID-19 Shots Shows Better Immune Response Than Original Vaccine
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice | Nature Medicine
Moderna Is Developing Two Different Omicron-Targeting Booster Shots - WSJ
